GeneDx has appointed Everett Cunningham as its chief executive, effective on or before 15 December 2026, succeeding Katherine Stueland after his brief tenure leading rival diagnostics company Quanterix. The appointment was announced on Tuesday, 18 November 2026, and reported on Wednesday, 19 November.
FAKTA
- New chief executive: Everett Cunningham, appointed chief executive officer and a member of the board of GeneDx, effective on or before 15 December 2026.
- Outgoing chief executive: Katherine Stueland, who steps down as chief executive and board member when Cunningham joins, and stays on as an adviser through 31 January 2027.
- Where he comes from: Quanterix Corporation, where Cunningham served as president and chief executive from January to November 2026.
- Experience: More than 35 years in diagnostics and commercial leadership, including roles at Illumina, Exact Sciences, GE HealthCare and Quest Diagnostics.
- Pay package: A base salary of $750,000, a 100 per cent target annual cash bonus, a $1.05 million sign-on bonus, and equity awards with a combined target value of $20 million.
- The company: GeneDx (Nasdaq: WGS) is a leader in rare disease diagnosis, using genomic data to improve health.

The appointment
GeneDx said its board of directors has appointed Cunningham as chief executive and a member of the board. He succeeds Stueland, who announced her departure after leading the company’s transformation. GeneDx said the change is not related to a disagreement over the company’s operations, policies or practices.
Mark Gardner will continue to serve as president, reporting to Cunningham. GeneDx also reaffirmed its full-year 2026 financial guidance, as provided on 9 November 2026 alongside its third-quarter financial results.
A short stay at Quanterix
Cunningham joins GeneDx from Quanterix, a global leader in precision biomarker science, where he served as president and chief executive and a director from January 2026 to November 2026. On the same day, Quanterix announced that Cunningham had stepped down as president and chief executive and as a member of its board, effective immediately, to accept an opportunity in another area of the healthcare sector.
Quanterix has appointed Jim Gute, its chief commercial officer since August 2026, to the additional role of interim president and chief executive while it searches for a permanent successor. Cunningham will remain available to Quanterix to assist with an orderly transition through 11 December 2026. Quanterix also reaffirmed its 2026 business outlook.
The transition at a glance
| Role | Person | Timing |
|---|---|---|
| GeneDx chief executive (incoming) | Everett Cunningham | Starts on or before 15 December 2026 |
| GeneDx chief executive (outgoing) | Katherine Stueland | Steps down when Cunningham joins; adviser to 31 January 2027 |
| GeneDx president | Mark Gardner | Continues, reporting to Cunningham |
| Quanterix interim chief executive | Jim Gute | Appointed 19 November 2026 while a permanent successor is sought |
Who Cunningham is
Cunningham is a veteran diagnostics and commercial leader with more than 35 years of experience. Before Quanterix, he held leadership roles at Illumina, Exact Sciences, GE HealthCare and Quest Diagnostics, four of the best-known names in diagnostics and laboratory testing. His appointment brings a commercial operator to a company that has built its position on rare-disease diagnosis.
His pay package reflects the board’s expectations. Alongside the $750,000 base salary and the $1.05 million sign-on bonus, he receives a $10 million time-based restricted stock unit award and a $10 million performance-based restricted stock unit award, with a further $4 million annual refresh performance award planned for fiscal year 2027.
What GeneDx does
GeneDx, based in Gaithersburg, Maryland, describes itself as the leader in rare disease diagnosis and in improving health through the power of genomic data. The company provides genetic testing that helps doctors diagnose rare diseases, and its next phase of growth is the task Cunningham has been hired to lead.
Conclusion
Cunningham’s move from Quanterix to GeneDx is one of the fastest chief-executive switches in the diagnostics industry this year: he led Quanterix for less than a year before taking the top job at a rival. For GeneDx, the appointment brings an experienced commercial leader; for Quanterix, the search for a permanent successor begins under an interim chief.































